Neither company's valuation reflects the value of Arestvyr. The litigation is a #$%$ shoot and an overhang for both stocks, and will stretch into 2014 since whatever Parson decides is headed back to the Supreme Court. The companies are in the same industry addressing the same customers. Redundant costs could get cut. PharmAthene has a promising drug but needs money. SIGA will start receiving significant cash this quarter and could help fund development. The bad blood is way overstated. Drapkin was the source of the contention and he is long gone. Parsons essentially called him a liar which fits with the testimony and e-mail traffic. I am long SIGA and I wish common sense would take hold with both companies. No one can handicap this case. The Supreme Court punted sending the damages back to Parson with no guidance on whether his award was justified under either promissory estoppel or failure to negotiate in good faith. Time to move on.
Actually, both companies together reflect the worth of Arestvyr otherwise one of the two would be soaring. If Arestyvr had any true value a third company would buy both SIGA and PIP. Smart money however has avoided both. These two companies serve only as a playground for day traders and posters with multiple IDs.